$13.320
-0.482 (-3.62%)Zum Schluss
Umsatzquellen von AVAH
Aveanna Healthcare Holdings Inc (AVAH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Private Duty Service, accounting for 82.6% of total sales, equivalent to $553.93M. Other significant revenue streams include Our Home Health & Hospice and Medical Solutions. Understanding this composition is critical for investors evaluating how AVAH navigates market cycles within the Healthcare Facilities & Services industry.
Profitabilität und Margen von AVAH
Evaluating the bottom line, Aveanna Healthcare Holdings Inc maintains a gross margin of 32.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.58%, while the net margin is 6.01%. These profitability ratios, combined with a Return on Equity (ROE) of 198.57%, provide a clear picture of how effectively AVAH converts its operational activities into shareholder value.
AVAH im Vergleich zur Peergroup
In the context of the broader market, AVAH competes directly with industry leaders such as ACHC and WGS. With a market capitalization of $2.69B, it holds a significant position in the sector. When comparing efficiency, AVAH's gross margin of 32.17% stands against ACHC's 100.00% and WGS's 68.37%. Such benchmarking helps identify whether Aveanna Healthcare Holdings Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Aveanna Healthcare Holdings Inc
Aveanna's financial performance shows a positive trend with total revenue increasing from $509 million in Q3 2024 to $670 million in Q2 2026. The net income has also improved significantly, with a reported net income of $40.29 million in Q2 2026 compared to a loss of $42.84 million in Q3 2024. The gross margin has stabilized around 32% in recent quarters, further supporting its profitability.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.